Advertisement

Topics

Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome

2010-07-15 17:00:00 | BioPortfolio

Summary

The purpose of the study is to evaluate the safety and tolerability of multi-dose, open-label LX606 in subjects with symptomatic carcinoid syndrome.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Symptoms of Carcinoid Syndrome

Intervention

Low Dose LX1606 - Day 1 (start), Mid-low dose LX1606 - Day 15 (start), Mid-high dose LX1606 - Day 29 (start), High dose LX1606 - Day 43 (start), Open Label Dose Extension

Location

Lexicon Investigational Site
Berlin
Germany

Status

Recruiting

Source

Lexicon Pharmaceuticals

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [11592 Associated Clinical Trials listed on BioPortfolio]

Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

The purpose of this study is to evaluate the safety and tolerability of LX1606 versus a placebo control in subjects with symptomatic carcinoid syndrome not managed by stable-dose long-acti...

A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

This study is a multisite, randomized, double-blind, placebo-controlled, phase 2 study of MG01CI (low dose and high dose once daily) for 6 weeks compared with placebo in a 1:1 ratio of 60 ...

Magnesium Sulfate in Obese Preeclamptics

The purpose of this study is to learn how medications participant will receive in the course of their delivery are metabolized (broken down by the body). The investigators hope to learn mo...

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC PB1046 in Subjects With Symptomatic PAH

This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of PB1046 at the optimally titrated dose after 16 weeks of trea...

Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients

The study consists of a 12 week run-in period when all subjects are stabilized on a single dose of Avalide (300 mg/12.5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends, subj...

PubMed Articles [17055 Associated PubMed Articles listed on BioPortfolio]

Dose gradient curve: A new tool for evaluating dose gradient.

Stereotactic radiotherapy, which delivers an ablative high radiation dose to a target volume for maximum local tumor control, requires a rapid dose fall-off outside the target volume to prevent extens...

Efficacy of High-Dose Methotrexate in Pediatric Non-Infectious Uveitis.

To analyze the efficacy of high dose (≥ 15mg/m2/week) methotrexate (MTX) versus low dose (

Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: A pooled analysis of individual data from 17 observational studies.

Cigarette smoking is associated with earlier menopause, but the impact of being a former smoker and any dose-response relationships on the degree of smoking and age at menopause have been less clear. ...

The effect of pre-dose on thermally and optically stimulated luminescence from α-AlO:C,Mg and α-AlO:C.

We report the effect of pre-dose on the thermoluminescence (TL) and optically stimulated luminescence (OSL) dose response of α-AlO:C,Mg and α-AlO:C. Before any luminescence measurement, the samples ...

The effect of pre-phototest sun exposure on minimal erythema dose (MED) and minimal melanogenic dose (MMD) among skin phototypes III, IV and V.

Ethnicity, skin phototype and colour influenced minimal erythema dose (MED). Sun exposure has been postulated to increase MED. We determined immediate pigment darkening dose to UVA (IPDDA), MED and mi...

Medical and Biotech [MESH] Definitions

The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.

A treatment schedule in which the total dose of radiation is divided into large doses.

The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)

Administration of the total dose of radiation (RADIATION DOSAGE) in parts, at timed intervals.

The ratio of the dose that produces toxicity to the dose that produces a clinically desired or effective response.

More From BioPortfolio on "Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial